Physician profile
Robert Baye
NPI 1780607549
$2,803.05
in general payments reported to CMS, 2019-2025
18 companies · $1,274 in 2025
The $1,274 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $480 · 2023: $24.29 · 2024: $1,024 · 2025: $1,274.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,113 · Education: $210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,112.62 |
| Education | $209.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $823.39 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Regeneron Healthcare Solutions, INC. | $560.93 | 2021-2025 | Dupixent |
| Glaxosmithkline, LLC. | $297.60 | 2021-2025 | Nucala, Trelegy Ellipta |
| Genentech USA, INC. | $256.09 | 2024-2025 | Xolair |
| Genzyme Corporation | $147.92 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $132.74 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2024 | |
| Csl Behring | $75.42 | 2024-2025 | Haegarda, Hizentra |
| Ars Pharmaceuticals Operations, INC. | $74.75 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $61.17 | 2024 | Cuvitru, Hyqvia, Eohilia |
| Optinose US, INC. | $57.51 | 2024 | |
| Boston Scientific Corporation | $48.90 | 2023-2024 | Watchman, Rhythmia Mapping System |
| Pharming Healthcare, INC. | $43.12 | 2025 | Ruconest |
| Mylan Specialty L.P. | $35.23 | 2021 | |
| Verona Pharma, INC. | $31.06 | 2025 | Ohtuvayre |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.72 | 2021 | |
| Biocryst US Sales Co., LLC | $20.64 | 2024 | Orladeyo |
| Pfizer INC. | $12.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Baye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.